. 2014 Dec 3;20:2520–2526. doi: 10.12659/MSM.891394

Table 1.

Key characteristics of trials included.

Study	Country	Ethnicity	SNP	Genotyping method	Source of Controls	Age (Case/control or case)	Patient	Sample size		Quality Score
Study	Country	Ethnicity	SNP	Genotyping method	Source of Controls	Age (Case/control or case)	Patient	Case	Control	Quality Score
^*de Mello et al. 2013	Portugal	Caucasian	rs833061	MassARRAY	HB	61.5/48	NSCLC	144	144	34
Lee et a. 2005	Korea	Asian	rs833061	PCR–RFLP	PB	61.6/60.9	Lung cancer	432	432	28
Sun et al. 2013	China	Asian	rs833061	PCR–RFLP	PB	56.7/55.2	Lung cancer	126	160	32
Zhai et al. 2008	USA	Caucasian	rs833061	TaqMan	HB	65/58	NSCLC	1,900	1,458	32
^*Heist et al. 2008	USA	Caucasian	rs833061	TaqMan	–	69	Early NSCLC	462	–	–
^*Masago et al. 2009	Japan	Asian	rs833061	TaqMan	–	67	Advanced NSCLC	126	–	–
^*Guan et al. 2010	China	Asian	rs833061	PCR–RFLP		35 to 88	Advanced NSCLC	124	–	–
de Mello et al. 2013	Portugal	Caucasian	rs699947	MassARRAY	HB	61.5/48	NSCLC	144	144	34
Deng et al. 2014	China	Asian	rs699947	PCR–RFLP	PB	55.8/53.8	Lung cancer	65	110	33
Li et al. 2012	China	Asian	rs699947	PCR–RFLP	PB	N.A.	Lung cancer	150	150	25
Liang et al. 2009	China	Asian	rs699947	PCR–RFLP	PB	57.5/56.9	Lung cancer	171	172	31

HB – hospital based control; PB – population based control; PCR-RFLP – polymerase chain reaction-restriction fragment length polymorphism; NSCLC – non-small-cell lung cancer;

studies assessing SNP and lung cancer survival; vacancy means not applicable.